Prokidney (PROK) Total Non-Current Liabilities (2021 - 2026)
Prokidney's (PROK) quarterly Total Non-Current Liabilities came in at $25.1 million in Q2 2026, down 21.0% year-over-year from $31.8 million in Q2 2025, and down 12.24% quarter-over-quarter from $28.6 million in Q1 2026.
Analysis
Prokidney (PROK) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Total Non-Current Liabilities for 6 consecutive years, with $25.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 21.0% year-over-year to $25.1 million in Q2 2026; TTM through Jun 2026 was $25.1 million, a 21.0% decrease from a year earlier, with the FY2025 full-year figure at $33.7 million, down 12.87% from the prior year.
- Total Non-Current Liabilities was $25.1 million for Q2 2026 at Prokidney, down from $28.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $38.7 million in Q4 2024 and troughed at $11.6 million in Q3 2022.
- A 5-year average of $26.4 million and a median of $27.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 124.18% in 2023 and dropped 21.0% in 2026, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $12.8 million in 2022, then jumped by 124.18% to $28.6 million in 2023, then soared by 35.05% to $38.7 million in 2024, then slipped by 12.87% to $33.7 million in 2025, then declined by 25.52% to $25.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $25.1 million (Q2 2026), $28.6 million (Q1 2026), and $33.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 134.44 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 898.00 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 72.64 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 117.70 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 577.71 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 313.33 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 126.64 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 1.66 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 130.91 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | 25.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.10 Mn |
| Mar 31, 2026 | 28.61 Mn |
| Dec 31, 2025 | 33.71 Mn |
| Sep 30, 2025 | 32.31 Mn |
| Jun 30, 2025 | 31.78 Mn |
| Mar 31, 2025 | 35.32 Mn |
| Dec 31, 2024 | 38.69 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 26.23 Mn |
| Mar 31, 2024 | 24.16 Mn |
| Dec 31, 2023 | 28.65 Mn |
| Sep 30, 2023 | 23.10 Mn |
| Jun 30, 2023 | 26.78 Mn |
| Mar 31, 2023 | 13.75 Mn |
| Dec 31, 2022 | 12.78 Mn |
| Sep 30, 2022 | 11.56 Mn |
| Dec 31, 2021 | 13.38 Mn |